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Abstract
The aminoglycosides amikacin (AMK)/kanamycin (KAN) and the cyclic polypeptide
capreomycin (CAP) are important injectable drugs in the treatment of multidrug-resistant
tuberculosis. Cross-resistance among these drug classes occurs and information on the
minimum inhibitory concentrations (MICs), above the normal wild-type distribution, may be
useful in identifying isolates that are still accessible to drug treatment. Isolates from the
Eastern Cape Province of South Africa were subjected to DNA sequencing of the rrs
(1400-1500 region) and tlyA genes. Sequencing data were compared with (i) conventional
susceptibility testing at standard critical concentrations (CCs) on Middlebrook 7H11 agar and
(ii) MGIT 960-based MIC determinations to assess the presence of AMK- and CAP-resistant
mutants. Isolates with an rrs A1401G mutation showed high-level resistance to AMK
(>20 mg/L) and decreased phenotypic susceptibility to CAP (MICs 10-15 mg/L). The MICs of
CAP were below the bioavailability of the drug, which suggests that it may still be effective
against multi- or extensively drug resistant tuberculosis [M(X)DR-TB]. Agar-based CC testing
was found to be unreliable for resistance recognition of CAP in particular.
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The aminoglycosides amikacin (AMK)/kanamycin (KAN) and the cyclic polypeptide capreomycin (CAP) are
important injectable drugs in the treatment of multidrug-resistant tuberculosis. Cross-resistance among these drug
classes occurs and information on the minimum inhibitory concentrations (MICs), above the normal wild-type
distribution, may be useful in identifying isolates that are still accessible to drug treatment. Isolates from the
Eastern Cape Province of South Africa were subjected to DNA sequencing of the rrs (1400–1500 region) and tlyA
genes. Sequencing data were compared with (i) conventional susceptibility testing at standard critical concen-
trations (CCs) on Middlebrook 7H11 agar and (ii) MGIT 960-based MIC determinations to assess the presence of
AMK- and CAP-resistant mutants. Isolates with an rrs A1401G mutation showed high-level resistance to AMK
(>20 mg/L) and decreased phenotypic susceptibility to CAP (MICs 10–15 mg/L). The MICs of CAP were below
the bioavailability of the drug, which suggests that it may still be effective against multi- or extensively drug
resistant tuberculosis [M(X)DR-TB]. Agar-based CC testing was found to be unreliable for resistance recognition of
CAP in particular.
Introduction
T herapeutic options in the treatment of pulmonary tu-berculosis (TB) are limited and this is a major concern in
view of the increasing incidence of drug-resistant Mycobacter-
ium tuberculosis. First-line drugs, especially isoniazid (INH) and
rifampicin (RMP), are the most effective and best tolerated
amongst the antituberculosis drugs.3,23 Resistance to at least
INH and RMP indicates that multidrug-resistant tuberculosis
(MDR-TB) has emerged.3 Treatment of MDR-TB requires pro-
longed administration of expensive and less-potent second-line
drugs, which are often poorly tolerated.3,23,24 MDR-TB patients
are thus at an increased risk of acquiring additional resistance,
which will eventually give rise to extensively drug resistant
(XDR)-TB.6 XDR-TB has independently emerged worldwide
and is defined as MDR-TB that has acquired additional resis-
tance to any fluoroquinolone (FQN) such as ofloxacin (OFX)
and also at least one of the three injectable second-line drugs:
amikacin (AMK) kanamycin (KAN), or capreomycin (CAP).3,6
The standard MDR-TB treatment regimen used in South
Africa is based on the recommended guidelines of the World
Health Organization (WHO) and includes the following
drugs: KAN or AMK (injectable), OFX, terizidone, ethion-
amide, and pyrazinamide.23,24 The FQNs and the injectables
(aminoglycosides and polypeptides) are the only bactericidal
agents among the second-line drugs.8,24 These drugs are
therefore essential in the treatment of MDR-TB, because they
have an equal role to play as INH and RMP among the first-
line drugs.14,24 AMK and KAN are aminoglycosides that
have a high level of cross-resistance between them.1,10,12 The
cyclic polypeptide CAP is structurally unrelated to the ami-
noglycosides and thus is a potential candidate to replace
AMK or KAN if resistance to either of them is suspected.2,9,24
Evidence that CAP is bactericidal against nonreplicating
M. tuberculosis has renewed interest in this drug, despite its
limitations because of renal and auditory toxicities.8 It has
been also demonstrated that the risk of treatment failure and
mortality increase when CAP resistance emerges among
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MDR-TB cases.14 However, cross resistance in M. tuberculosis
between AMK/KAN and CAP has been observed in both
clinical isolates and laboratory-generated mutants.4,10,12,22
AMK/KAN and CAP primarily affect protein synthesis in
M. tuberculosis and resistance to these drugs is associated with
changes in the 16S rRNA (rrs).1,9,12,13,16,22 The rrs mutation
A1401G causes high-level AMK/KAN and low-level CAP
resistance. C1402T is associated with CAP resistance (also
viomycin) and low-level KAN resistance. G1484T is linked to
high-level AMK/KAN and CAP resistance (including vio-
mycin).4,10,12,13,19 Various single-nucleotide polymorphisms
(SNPs) in the tlyA gene have been also associated with CAP
resistance.17 The tlyA gene encodes a putative rRNA methyl-
transferase and mutations that inactivate this gene in M. tu-
berculosis result in CAP and viomycin resistance.9,13
The Eastern Cape Province is a region in South Africa
where the incidence of drug-resistant TB is high. The pur-
pose of this study was to investigate a subset of M(X)DR-TB
clinical isolates of M. tuberculosis from this region to (i) cor-
relate the phenotypic susceptibility levels of AMK and CAP
with the molecular mechanisms that cause drug resistance
and (ii) consider possible applications of our findings in




Between June 2008 and November 2009, 310 M(X)DR TB
isolates of M. tuberculosis, collected by the National Health
Laboratory Services (NHLS) in the Eastern Cape of South
Africa, were sent to Stellenbosch University for genotyping.
The isolates were initially cultured by the NHLS in Port
Elizabeth and subjected to routine drug susceptibility testing
(DST) of first- and second-line drugs. AMK was tested at a
critical concentration (CC) of 4.0 mg/L7 and CAP at 10 mg/L24
on Middlebrook 7H11 agar. A subset of 50 M(X)DR-TB iso-
lates was selected from the above group with each isolate
representing a separate patient. The cohort included strains
that were susceptible to both AMK and CAP, resistant to
AMK, and resistant to both drugs (Table 1). The test isolates
were subdivided according to their drug susceptibility pat-
terns into three groups: MDR (19 of these showed additional
resistance to one or more of the alternative antituberculosis
drugs, excluding the FQNs and the injectable drugs), pre-XDR
(MDR with additional resistance to either an FQN or an
injectable),22 and XDR.
Each of the 50 isolates was retested in our laboratory by
semiquantitative DST (QDST) to assess the level of AMK and
CAP resistance. The automated BACTEC MGIT 960 instru-
ment (BD Bioscience) equipped with the TBeXiST application
and EpiCentre V5.69A software (BD Bioscience) was used
for QDST as previously described.20 AMK was tested at 1.0,
4.0, and 20.0 mg/L and CAP at 2.5, 5.0, 10.0, 15.0, and
25.0 mg/L. M. tuberculosis strain H37Rv (ATCC 27294) was
included as a control and subjected to all the relevant drug
concentrations. Strains with minimum inhibitory concentra-
tions (MICs) of 1.0 mg/L for AMK and 2.5 mg/L for CAP
were considered as resistant based on the CCs suggested by
the WHO.24 Ethical approval for the study (N09/11296) was
given by the Faculty of Health Science at Stellenbosch Uni-
versity.
Polymerase chain reaction amplification
and DNA sequencing
Mutations in the rrs and tlyA genes were identified by
polymerase chain reaction (PCR) amplification with primers
that were designed in-house using Primer3 (v. 0.40).15 The
Table 1. Mutations and Susceptibility Profiles of Amikacin and Capreomycin




960b MIC in mg/Lc Gene mutationsd
Resistance classification
No. of clinical isolates AMK CAP AMK CAP rrs gene tlyA gene
XDR
6 R S >20 (R) 10 (R)
A1401G None7 R R >20 (R) 10 (R) g
2 R R >20 (R) 15 (R)
Pre-XDR
6 R S >20 (R) 10 (R)
A1401G None
1 R S >20 (R) 15 (R) g7 R R >20 (R) 10 (R)
1 R R >20 (R) 15 (R)
MDR
5 S S >20 (R) 10 (R) g A1401G None15 S S <1.0 (S) 2.5 (S) None None
Control
H37Rv (ATCC 27294) S S <1.0 (S) 2.5 (S) Not done Not done
aCritical concentrations on 7H11 agar: AMK, 4.0 mg/L; CAP, 10 mg/L.
bQDST, quantitative drug susceptibility testing.
cCritical concentrations in MGIT 960 medium: AMK, 1.0 mg/L; CAP, 2.5 mg/L.
dThe entire tlyA gene and region 1400–1500 of the rrs gene were sequenced.
DST, drug susceptibility testing; QDST, quantitative DST; MIC, minimum inhibitory concentration; AMK, amikacin; CAP, capreomycin; S,
susceptible; R, resistant.
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1400-bp region of the rrs gene (position 1339–1528) was
amplified with the following primers: rrs290_F 50-TGCTAC
AATGGCCGGTACAA-30 and rrs290_R 50-CTTCCGGTACG
GCTACCTTG-30.
Amplification of the entire tlyA gene (including 31 and 33
bases upstream and downstream of the gene, respectively)
was done with the following primers: tlyA_F 50-CTGGAG
TCGGCGGAGAAG-30 and tlyA_R 50-GGACGACCAGCAG
AACACTG-30.
Briefly, 200ml of a primary MGIT subculture was heat in-
activated by incubating at 1008C for 30 min to generate a crude
DNA lysate. Each reaction mixture used for PCR amplification
contained 2ml crude DNA template, 5ml Q-Buffer, 2.5ml of
10Buffer, 2ml of 25 mM MgCl2, 4ml of 10 mM dNTPs, 1ml of
the forward and reverse primers, and 0.125ml HotStarTaq DNA
polymerase (Qiagen), and double-distilled H2O was then ad-
ded to make a final volume of 25ml. Amplification was initiated
by incubation at 958C for 15 min, followed by 35–45 cycles at
948C for 45 sec, 628C for 45 sec, and 728C for 45 sec. After the
last cycle, the samples were incubated at 728C for 10 min. The
preparation of the PCR reaction mixes, the addition of the
DNA, and the PCR amplification were conducted in separated
rooms to minimize laboratory cross-contamination. Negative
controls (H2O) were included to detect reagent contamination.
Amplification was confirmed by electrophoretic fractionation
in 1% agarose containing Tris-borate (TBE)-EDTA (pH 8.3).
Amplification products were sequenced using the ABI3130XL
genetic analyzer (Applied Biosystems) and the resulting chro-
matograms were analyzed using Chromas software.
Antimicrobial agents
AMK (disulfate salt) and CAP (capreomycin sulfate) were
purchased from Sigma Aldrich. Stock solutions of the drugs
were prepared in distilled water. The drugs were then filter-
sterilized and stored at 808C for up to 6 months.
Results
DNA sequencing of the rrs gene detected the A1401G
mutation in 181 of the 310 isolates (58%). Routine DST on
Middlebrook 7H11 agar at standard AMK and CAP CCs7,24
indicated that 89.5% (162/181) of the isolates with an rrs
A1401G mutation were resistant to AMK and 13% (21/162) of
these had resistance to both AMK and CAP. Of the remaining
129 isolates that lacked an rrs A1401G mutation, 6% (8/129)
were resistant to AMK and one of these (1/8) was resistant to
both AMK and CAP. Of the 310 isolates, 50 were selected to
represent a variety of drug-resistant patterns for further
analysis (Table 1). This selection was based on data initially
obtained from routine DST on Middlebrook 7H11 agar plates.
The level of AMK and CAP resistance was subsequently
quantified by QDST in MGIT 960 and these findings were
then compared with those obtained from CC testing. A com-
parison of the phenotypic and genotypic drug resistance is
summarized in Table 1. According to routine DST on 7H11
agar, 20 of the 50 M(X)DR isolates tested were susceptible to
both AMK (CC of 4.0 mg/L)7 and CAP (CC of 10.0 mg/L).24
However, QDST by MGIT 960 at CCs of 1.0 mg/L for AMK
and 2.5 mg/L for CAP showed that five of the former isolates
(5/20) were resistant to both drugs. The latter five isolates also
displayed an rrs A1401G mutation, which is expected to me-
diate cross-resistance between AMK and CAP.4,10,12,22 Both
phenotypic methods found the other 15 isolates (15/20),
which lacked mutations in the genes investigated to be truly
susceptible to AMK and CAP. The remaining 30/50 strains
also tested resistant to both AMK and CAP by MGIT 960
QDST. On the other hand, routine DST only found 17 of the 30
strains resistant to both AMK and CAP, and 13 were resistant
to AMK only. The MICs of AMK and CAP in the resistant
strains by MGIT 960 were >20 mg/L and 10–15 mg/L, re-
spectively. These results correlate with recently published
data.4 No mutations were detected in the 1400–1500 region of
the rrs gene in any of the 15 AMK-CAP–susceptible isolates,
and all 50 isolates had wild-type tlyA genes. The agreement
between the two phenotypic methods to detect isolates sus-
ceptible to both AMK and CAP was 15/20 (75%), to indicate
AMK resistance was 30/35 (85.7%), and to predict the pres-
ence of both AMK and CAP resistance was 17/35 (48.6%).
Discussion
In this study, a complete correlation between the MGIT
960 QDST results and the presence of a nucleotide substi-
tution at position 1401(A?G) in the rrs gene of all 35 AMK-
resistant strains was observed. Our findings are therefore in
accordance with existing data, which clearly demonstrate
that a mutation at rrs position 1401 not only confers high-
level AMK/KAN resistance in M. tuberculosis, but also de-
creases susceptibility to CAP.4,5,10,22 In contrast, agar-based
CC testing was compromised by significant discordance
between phenotypic and genetic resistance testing, particu-
larly for CAP. Methodological differences may account for
the discrepancies between CC testing on 7H11 plates and
QDST in MGIT 960, especially where borderline results were
anticipated. Borderline resistance is associated with in-
creased MICs that are only moderately higher than the CC of
a given drug. An MIC range of 4–32 mg/L on 7H10 agar has
been recently demonstrated for CAP against M. tuberculosis
isolates that contain the rrs (A1401G) SNP.4 These MIC val-
ues were scattered around the CC (10 mg/L) that is currently
used in 7H10 agar for routine DST of CAP.4,24 Clustering of
MICs around the CC reflects borderline resistance, which
may lead to false-susceptibility results and variability in re-
porting methods. It is also evident from related studies that
the current CC for CAP in 7H10 agar is probably too high
and 4 mg/L has been suggested to match the 2.5 mg/L for
MGIT 960.4,11,24 Disparity in CCs and borderline resistance to
CAP could have contributed to the discrepancies between
the two methods of susceptibility testing that we observed in
this study. However, an SNP at position 1401 in the rrs gene
confers high-level resistance to AMK4,10 and these reasons do
not justify the conflicting results obtained with this drug.
The results of the test isolates from patients in the Eastern
Cape reflect a history of AMK/KAN usage prior to CAP
treatment. It is likely that decreased susceptibility to CAP
occurred even before it was added to the treatment regimen.
The preselection of low-level CAP resistance as a result of
AMK/KAN therapy may imply that the drug has no further
clinical relevance in the treatment of XDR patients. However,
conventional DST is based on a single CC, which does not
necessarily reflect clinical resistance.20 Peak serum concen-
tration levels of 20–47 mg/L for CAP are achieved between 1
and 2 hr after a single daily dosage of 15–20 mg/kg by in-
tramuscular injection.2 In this study, the MICs (10–15 mg/L)
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of the CAP-resistant isolates were above the CC of 2.5 mg/L
as recommended by WHO,24 but substantially below the
achievable peak serum levels.2 Protein binding of CAP is
relatively low at 20% and the concentration of free drug at the
point of infection may be sufficient for an adequate thera-
peutic effect in patients infected with low-level CAP-resistant
mutants.2 Therapeutic options for M(X)DR-TB are severely
restricted and the omission of CAP based on the current DST
criteria needs to be considered with caution. QDST provided
valuable information on the degree of CAP resistance, which
could be useful in classifying clinical isolates as susceptible
(wt), intermediate, or resistant.18 We associate intermediate
resistance to CAP with a distinct MIC cluster between sus-
ceptible and definite resistant strains. The results obtained in
this study demonstrate that the rrs A1401G mutation confers
an intermediate level of resistance to CAP in the isolates from
the Eastern Cape. However, the therapeutic effect of CAP
against such strains is currently uncertain. It is therefore re-
commended that a clear correlation between multiple break-
points above the standard CC for CAP and patient outcome is
established through well-designed clinical studies.
Conclusions
This investigation supports existing data that the A1401G
mutation in the rrs gene mediates resistance to AMK/KAN
and decreased susceptibility to CAP.4,10 The susceptibility
results obtained in this study with MGIT 960 for AMK and
CAP were in exact concordance with the nucleic acid se-
quence data, whereas significant differences were found with
7H11 agar. In addition, the MGIT 960 results were based on
multiple MIC concentrations as opposed to a single CC used
for 7H11. In view of these reasons, we consider the MGIT
results superior to those obtained by 7H11 agar. Further, the
automated MGIT 960 system is technically less demanding
and has a much shorter turnaround time than the standard
7H11 agar method. Given the unreliability of routine agar-
based CC testing, we favor the view that MGIT 960-based
testing should become the standard for second-line DST,21 as
it is suitable for both CC testing and QDST when equipped
with TBeXiST and EpiCentre software.20
Our findings recommend the use of this technology to-
gether with pharmacokinetic and pharmacodynamic pa-
rameters for the management of M(X)DR-TB in the Eastern
Cape, where nearly 60% of MDR cases harbor the rrs A1401G
mutation.
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